JPMorgan Upgrades Alkermes (ALKS) to Overweight. PT $78
- Futures dip as focus turns to Fed meeting
- BOJ hikes interest rates for first time in 17 years, to remain accommodative
- Buy the dip in US stocks in case of a 'rate shock' - Goldman
- Shares dip, yen slides as BOJ's landmark policy shift draws eyes
- Nvidia unveils Blackwell, AI chip 'to power this new industrial revolution'
- Canoo Inc. (GOEV) Provides Update on $62M Share Pre-Paid Advance Agreement
- StoneCo (STNE) Tops Q4 EPS by 33c
- Super Micro Computer (SMCI) Announces Proposed 2M Share Offering
- JOANN Inc (JOAN) Enters Agreement to Reduce Debt and Receive $132 Mln in New Capital
- Cisco Systems (CSCO) Completes Acquisition of Splunk (SPLK)
Alkermes (ALKS) PT Raised to $70 at Credit Suisse
October 21, 2016 9:29 AM EDTCredit Suisse analyst Vamil Divan reiterated an Outperform rating and raised its price target on Alkermes (NASDAQ: ALKS) to $70.00 (from $52.00) after the company released positive data after the close from the third Phase 3 study for their pipeline anti-depression drug ALKS-5461.
Divan... More
Alkermes (ALKS) PT Raised to $70 at Jefferies
October 21, 2016 7:22 AM EDTJefferies analyst Biren Amin reiterated a Buy rating an lifted his price target on Alkermes (NASDAQ: ALKS) to $70.00 (from $62.00) after ALKS 5461 for MDD at 2mg/2mg hit stat sig on MADRS-6 scale in FORWARD-5, the third of three PIII studies to assess efficacy of... More
Alkermes (ALKS) PT Raised to $70 at Leerink Partners
October 21, 2016 6:41 AM EDTLeerink Partners analyst Paul Matteis reiterated an Outperform rating and raised its price target on Alkermes (NASDAQ: ALKS) to $70.00 (from $57.00) after the company announced positive results from their third ph3 study for ALKS5461 in depression.
Matteis commented, "We were previously... More
Alkermes' (ALKS) FORWARD-5 Pivotal Phase 3 Study of ALKS 5461 for Major Depressive Disorder Mets Primary Endpoint
October 20, 2016 4:01 PM EDTAlkermes plc (NASDAQ: ALKS) today announced positive topline results from FORWARD-5, the third phase 3 efficacy study to read out from the FORWARD pivotal program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressant therapies. The... More
Alkermes plc (ALKS) Announces Third ALKS 5461 Phase 3 Met Primary Endpoint in MDD
October 20, 2016 4:00 PM EDTAlkermes plc (NASDAQ: ALKS) announced positive topline results from FORWARD-5, the third phase 3 efficacy study to read out from the FORWARD pivotal program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressant therapies. The study... More